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Role of nitric oxide in resveratrol-induced renal
protective effects of ischemic preconditioning
Vikas Chander, PhD, and Kanwaljit Chopra, PhD, Chandigarh, India
Background: Resveratrol, a natural antioxidant and polyphenol found in red wine and grapes, has been found to
pharmacologically precondition the heart through upregulation of nitric oxide (NO). This study was designed to explore
the involvement of NO in the renoprotective effect of resveratrol in renal ischemic preconditioning in rat kidney.
Methods: Ischemic preconditioning was induced by three cycles 2-minutes of ischemia followed by 5 minutes of
reperfusion before 45 minutes of prolonged ischemia. Resveratrol was given 1 hour before the surgical procedures.
Results: Ischemic preconditioning and resveratrol treatment significantly improved the renal dysfunction, decrease in total
NO levels, and oxidative stress induced by 45 minutes of ischemia followed by 24 hours of reperfusion. Histopatholgic
examination of the kidneys of ischemic/reperfusion rats revealed severe renal damage, which was attenuated in both
preconditioned and resveratrol-treated animals. Preconditioning and resveratrol administration led to a marked increase
in NO levels in kidney. Renoprotective effects of resveratrol were abolished when animals were pretreated with
NG-nitro-L-arginine methyl ester, a nonspecific NO synthase inhibitor.
Conclusions: These findngs demonstrate an important contributory role of NO in the protection afforded by resveratrol
in renal ischemic preconditioning. (J Vasc Surg 2005;42:1198–1205.)
Clinical Relevance: It is now well established that brief periods of ischemia followed by reperfusion render a variety of
tissues tolerant to subsequent ischemia/reperfusion-induced injury. This phenomenon, referred to as ischemic precon-
ditioning, was first demonstrated in the dog myocardium. The potential for clinical application of such a powerful
protective phenomenon has generated enormous interest in identifying the underlying intracellular signaling pathways,
with the ultimate aim of pharmacologically exploiting these mechanisms to develop therapeutic strategies that can
enhance tolerance to ischemia/reperfusion injury in patients. This study explored the possible involvement of nitric oxide
in renal ischemic preconditioning.It is now well established that brief periods of ischemia
followed by reperfusion render a variety of tissues tolerant
to subsequent ischemia/reperfusion (I/R)-induced injury.
This phenomenon, referred to as ischemic preconditioning
(IP) by Murry et al,1 was first demonstrated in the dog
myocardium. Protective effects of IP on I/R injury have
subsequently been revealed in other species, including
pigs,2 rabbits,3 and rats,4 as well as in other organs, includ-
ing the rat small intestine,5 skeletal muscle,6 liver,7and
brain.8 However, evidence supporting a role for IP in
protecting against I/R injury in kidney is scant and contro-
versial.9,10 I/R injury in the kidney causes severe tissue
damage with typical functional and pathophysiological
characteristics, including diminished glomerular filtration
rate, tubular sodium reabsorption, and renal blood flow.
Tissue blood flow is dramatically improved in I/R injury of
the myocardium and skeletal muscle after IP.1-4,6 Although
the mechanisms of IP have yet to be fully elucidated,
activation of vasodilating factors (including adenosine
triphosphate–dependent potassium channels, adenosine
A1 receptors, or both
11; nitric oxide [NO]12; and protein
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1198kinase C13) and prevention of cell apoptosis through down-
regulation of caspases14 are thought to be involved.
NO plays an important role in regulating renal hemo-
dynamics and functions.15 A great deal of evidence has
suggested that NO is generated not only in the renal
vascular endothelium, but also in other renal cells, such as
mesangium, macula densa, and tubular cells,16 thereby
suggesting that endogenous NO plays an important role in
the regulation of renal blood flow, renal perfusion pressure,
renal vascular tone, renal tubular reabsorption, and glomer-
ular filtration rate. The role of NO in I/R-induced acute
renal failure is controversial.
Resveratrol (trans-3,5,4=-trihydroxy stilbene), a natu-
rally occurring phenolic compound, abundantly available in
grape skins and in wines, has been found to protect the
heart from I/R injury.17,18 It possesses diverse biochemical
and physiological actions, which includes estrogenic, anti-
platelet, and anti-inflammatory properties.19,20 Recently,
resveratrol was found to protect kidney, heart, and brain
from I/R injury.17,18,21,22 In kidney cells, resveratrol was
found to exert its protective action through upregulation of
NO.22 The ability of resveratrol to stimulate NO produc-
tion during I/R is believed to play a crucial role in its ability
to protect kidney cells from I/R injury.19,23
Ray et al24 have demonstrated the ability of resveratrol
to protect the ischemic reperfused myocardium by improv-
ing postischemic ventricular function and by attenuating
myocardial infarction due to both necrosis and apoptosis.
Although the in vivo antioxidant ability of resveratrol is
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protective properties of resveratrol, the mechanism of ac-
tion is not completely understood. Recently, a study by
Imamura et al25 demonstrated that resveratrol was unable
to precondition inducible NO synthase (iNOS) knockout
mouse hearts, whereas it could successfully precondition
wild-type mouse hearts, thus indicating an essential role of
iNOS in resveratrol preconditioning of the heart.
On the basis of these findings, the purpose of this study
was to determine whether I/R-induced renal dysfunction
and tissue injury can be overcome by IP and to determine
whether endogenous NO contributes to the protective
effect of resveratrol in preconditioning of the kidney.
MATERIALS AND METHODS
Surgical procedure
All protocols were approved by the Institutional Ani-
mal Ethical Committee of the Panjab University. The study
was performed on male Wistar rats weighing between 200
and 250 g. Animals were anesthetized with thiopental
sodium (40 mg/kg intraperitoneally) and placed in the
supine position under a heating lamp to maintain the body
temperature at 36°C to 37°C. To induce renal ischemia, a
midline laparotomy was performed, and the blood supply
to both kidneys was interrupted by occluding the renal
pedicles. Reflow was initiated by removing the occlusion.
Drugs
Resveratrol (Sigma, St Louis, Mo) was suspended in
0.5% sodium carboxy methyl cellulose, and NG-nitro-L-
arginine methyl ester (L-NAME; Sigma) was dissolved in
distilled water.
Histologic studies
Immediately after the animal was killed, the right kid-
ney was isolated and washed with ice-cold saline. It was
then fixed in a 10% neutral buffered formalin solution,
embedded in paraffin, and used for histopathologic exam-
ination. Five-micrometer-thick sections were cut, deparaf-
finized, hydrated, and stained with hematoxylin and eosin.
The renal sections were examined in blind fashion for
tubular cell necrosis, intertubular cell detachment, intersti-
tial edema, and medullary congestion in all treatments.
Abnormalities were graded by using a semiquantitative
scale from 0 to 4, in which 0 denotes no abnormalities;
1, changes affecting less than 25% of the sample; 2,
changes affecting 25% to 50% of the sample; 3, changes
affecting 50% to 75% of the sample; and 4, changes
affecting 75% of the sample.
Study design
Design A. To study the effect of IP in I/R and to
obtain the most suitable preconditioning schedule, an ex-
periment was performed with 42 animals classified into 6
groups:1. Sham-operated control group (n  6)
2. The ISC group had no preconditioning and 45 minutes
of bilateral ischemia followed by 24 hours of reperfusion
(n  6)
3. The Prec 2/5 group had three cycles of 2 minutes of
ischemia and 5 minutes of reperfusion (n  7) and 45
minutes of prolonged ischemia followed by 24 hours of
reperfusion
4. The Prec 3/5 group had three cycles of 3 minutes of
ischemia and 5 minutes of reperfusion (n  7) and 45
minutes of prolonged ischemia followed by 24 hours of
reperfusion
5. The Prec 4/5 group had three cycles of 4 minutes of
ischemia and 5 minutes of reperfusion (n  8) and 45
minutes of prolonged ischemia followed by 24 hours of
reperfusion
6. The Prec 5/5 group had three cycles of 5 minutes of
ischemia and 5 minutes of reperfusion (n  8) and 45
minutes of prolonged ischemia followed by 24 hours of
reperfusion
Design B. Using the best schedule of preconditioning
from design A, that is, 2 minutes of ischemia followed by 5
minutes of reperfusion (Prec 2/5; hereafter named IP), we
determined whether resveratrol-induced NO could medi-
ate IP. For this purpose, another set of experiments was
performed that included the following groups:
1. The ISC group had 45 minutes of ischemia followed by
24 hours of reperfusion (n  6)
2. The IP-ISC group had IP plus 45 minutes of ischemia
followed by 24 hours of reperfusion (n  7)
3. The NO-ISC group was administered resveratrol (5
mg/kg by mouth) 30 minutes before surgery and then
had 45 minutes of prolonged ischemia followed by 24
hours of reperfusion (n  6)
4. The NO-IP group was administered resveratrol (5
mg/kg by mouth) 30 minutes before surgery, then IP,
and then had 45 minutes of prolonged ischemia fol-
lowed by 24 hours of reperfusion (n  8)
5. The NA-IP group had the nonselective NO synthase
(NOS) blocker L-NAME (10 mg/kg intraperitoneally)
given 30 minutes before surgery, followed by the IP
protocol and, finally, 45 minutes of prolonged ischemia
before 24 hours of reperfusion (n  7)
6. The NO-NA-IP group had resveratrol (5 mg/kg by
mouth) and the nonselective blocker L-NAME (10
mg/kg intraperitoneally) administered 30 minutes be-
fore surgery, then IP, and then 45minutes of prolonged
ischemia followed by 24 hours of reperfusion (n  6)
7. The NA-ISC group had the nonselective blocker L-
NAME (10 mg/kg intraperitoneally) administered 30
minutes before surgery and then had 45 minutes of
prolonged ischemia followed by 24 hours of reperfusion
(n  6)
The animals were placed in individual metabolic cages
for 24 hours for urine collection. The animals were anes-
thetized with high doses of thiopentone sodium (60
JOURNAL OF VASCULAR SURGERY
December 20051200 Chander and Chopramg/kg intraperitoneally), and blood was collected in hep-
arinized centrifuge tubes through the abdominal aorta.
The blood samples were centrifuged, and plasma was col-
lected. A midline abdominal incision was performed, and
both kidneys were isolated. The left kidney was deep-frozen
until further enzymatic analysis, whereas the right kidney
was stored in 10% formalin for the histologic studies.
Assessment of renal function
Serum samples were assayed for blood urea nitrogen
(BUN) and serum creatinine by using standard diagnostic
kits (Span Diagnostics, Gujarat, India).
Postmitochondrial supernatant preparation and
biochemical estimations
After the animals were killed, their kidneys were quickly
removed, perfused immediately with ice-cold normal sa-
line, and homogenized in chilled potassium chloride
(1.17%) by using a Potter Elvehjem homogenizer. The
homogenate was differentially centrifuged to obtain post-
mitochondrial supernatant, which was used for further
enzymatic analysis.
Malondialdehyde, a measure of lipid peroxidation, was
assayed in the form of thiobarbituric acid–reacting sub-
stances (TBARS).26 The reduced glutathione (GSH) was
measured by the method of Jollow et al,27 and the yellow
color developed by the reduction of Ellman’s reagent by
–SH groups of GSH was read at 412 nm. Catalase activity
was assayed by the method of Claiborne,28 and the rate of
decomposition of H2O2 was followed at 240 nm. The
superoxide dismutase (SOD) activity was assessed by the
method of Kono.29 The nitro blue tetrazolium reduction
by superoxide anion to blue formazon was followed at
560 nm.
Tissue and urine nitrate and nitrite measurements
NO production in renal tissue and urine was deter-
mined by the standard Total Nitric Oxide Assay kit (Assay
Design, Inc). Nitrate was reduced to nitrite by 3 hours of
incubation with nitrate reductase in the presence of nico-
tinamide adenine dinucleotide 3-phosphate and flavin-
adenine-dinucleotide. Nitrite was converted into a deep
purple azo compound by the addition of Griess reagent.
The total nitrite/nitrate concentration was calculated by
using the standard of sodium nitrate. Results were ex-
pressed as micromoles per liter.
Statistical analysis
Values are expressed as means  SEM. One-way anal-
ysis of variance followed by the Dunnett t test was applied
to calculate the statistical significance between various
groups. A value of P .05 was considered to be statistically
significant.
RESULTS
Protective effect of preconditioning on ischemia to
establish the optimal preconditioning protocol. The
serum creatinine, BUN, and creatinine clearance profile isshown in Fig 1. Rats from the ISC group presented severe
renal failure as compared with sham-operated animals. The
serum creatinine and BUN in the Prec 2/5 group were
significantly lower than in the ISC group, whereas the Prec
3/5, 4/5, and 5/5 preconditioning schedules did not
protect against ischemia, because the serum creatinine and
BUN levels in the Prec 5/5 group were similar to those in
ISC rats. The creatinine clearance in ISC rats was signifi-
cantly lower as compared with sham-operated rats, whereas
creatinine clearance in the Prec 2/5 and 3/5 groups was
significantly improved. The creatinine clearance in the Prec
4/5 and 5/5 groups was similar to that of the ISC group.
Among preconditioning groups, rats with three cycles of 2
minutes of IP (Prec 2/5) had the best renal function.
Histologic evaluations revealed severe tubulointerstitial
damage in kidneys from the ISC group, whereas only the

































































Fig 1. Effect of ischemic preconditioning on serum creatinine
(A), blood urea nitrogen (BUN) (B), and creatinine clearance (C)
in ischemic reperfused rats. Values are expressed as mean  SEM.
*P  .05 compared with the sham group; **P  .05 compared
with the ISC group (one-way analysis of variance followed by the
Dunnett test). Prec 2/5, Three cycles of 2 minutes of ischemia and
5 minutes of reperfusion and 45 minutes of prolonged ischemia
followed by 24 hours of reperfusion; Prec 3/5, three cycles of 3
minutes of ischemia and 5 minutes of reperfusion and 45 minutes
of prolonged ischemia followed by 24 hours of reperfusion; Prec
4/5, three cycles of 4 minutes of ischemia and 5 minutes of
reperfusion and 45 minutes of prolonged ischemia followed by 24
hours of reperfusion; Prec 5/5, three cycles of 5 minutes of isch-
emia and 5 minutes of reperfusion and 45 minutes of prolonged
ischemia followed by 24 hours of reperfusion.logic damage, as evidenced by lower tubular necrosis, med-
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proteinaceous casts (Table I). The other preconditioning
groups showed tubulointerstitial damage similar to that in
the ISC group.
Effect of resveratrol and NOS inhibition on
preconditioning. Treatment with resveratrol in animals
subjected to 45 minutes of ischemia followed by 24 hours
of reperfusion decreased the serum creatinine and BUN
levels and increased the creatinine clearance as compared
with the ISC group (Table II). This indicates that resvera-
trol provides significant protection against dysfunction re-
sulting from ischemia. When NOS was inhibited nonselec-
tively with L-NAME, the effect of preconditioning was
abolished, and severe renal failure was observed, with an
increase in serum creatinine and BUN and a decrease in
creatinine clearance as compared with the ISC group (Ta-
Table I. Assay of optimal one-cycle preconditioning
schedule based on histologic studies
Group Score
Sham 0.5  0.01
ISC 3.2  0.5*
Prec 2/5 0.8  0.02†
Prec 3/5 2.4  0.2
Prec 4/5 3.1  0.5
Prec 5/5 3.5  0.4
Prec 2/5, Three cycles of 2 minutes of ischemia and 5 minutes of reperfusion
and 45 minutes of prolonged ischemia followed by 24 hours of reperfusion;
Prec 3/5, three cycles of 3 minutes of ischemia and 5 minutes of reperfusion
and 45 minutes of prolonged ischemia followed by 24 hours of reperfusion;
Prec 4/5, three cycles of 4 minutes of ischemia and 5 minutes of reperfusion
and 45 minutes of prolonged ischemia followed by 24 hours of reperfusion;
Prec 5/5, three cycles of 5 minutes of ischemia and 5 minutes of reperfusion
and 45 minutes of prolonged ischemia followed by 24 hours of reperfusion.
Samples were examined for tubular cell necrosis, tubular dilation, intratu-
bular cell detachment, interstitial edema, medullary congestion, and hem-
orrhage. Abnormalities were graded from 0 to 4 (0, no abnormalities, 1,
changes affecting 25% of the sample; 2, changes affecting 25%-50% of
the sample; 3, changes affecting 50%-75% of the sample; 4, changes
affecting 75% of the sample).
*P  .05 compared with sham.
†P  .05 compared with the ISC group.
Table II. Effect of resveratrol and nitric oxide synthase in
nitrogen [BUN], and creatinine clearance) in precondition
Group Plasma creatinine (mg/dL)
Sham 0.71  0.32
ISC 3.1  0.103*
IP-ISC 1.15  0.21†
NO-ISC 1.12  0.25†
NO-IP 0.69  0.19†
NA-IP 2.65  0.62
NO-NA-IP 1.36  0.26†
NA-ISC 3.81  0.1
Values are expressed as mean  SEM.
ISC, Ischemic group; IP-ISC, preconditioned group; NO-ISC, resveratrol 
 preconditioned group; NO-NA-IP, resveratrol  L-NAME  preconditi
*P  .05 compared with sham.
†P  .05 compared with the ISC group (one-way analysis of variance followed byble II). Furthermore, three (42.85%) of seven animals from
the NA-IP group died because of uremia, thus suggesting
that the ischemic damage was also greater. Accordingly, in
the group of nonpreconditioned animals receiving
L-NAME (the NA-ISC group), comparatively high mortal-
ity rates (50%; three of six) and severe renal failure were
observed. When resveratrol was added to the group of
preconditioned animals receiving L-NAME (the NO-
NA-IP group), serum creatinine, BUN, and creatinine
clearance levels were similar to those found in precondi-
tioning animals. Histologic evaluation showedmarked pro-
tection in the NO-ISC, NO-IP, and NO-NA-IP groups as
compared with the ISC, NA-IP, and NA-ISC groups (Fig
2; Table III).
Effect of preconditioning, resveratrol, and
L-NAME on biochemical parameters. Renal I/R (ISC
group) produced a significant increase in TBARS levels as
compared with sham-operated animals. The TBARS levels
were markedly reduced in preconditioning-treated animals
(IP-ISC, NO-IP, and NO-IP-ISC groups), and L-NAME–
treated animals (NA-ISC and NA-IP groups) showed no
decrease in TBARS levels (Table IV).
Renal I/Rmarkedly decreased the enzymatic activity of
GSH, catalase, and SOD. This reduction was significantly
improved by preconditioning (IP-ISC, NO-IP, and NO-
IP-ISC groups), but it was not observed in L-NAME–
treated (NA-ISC and NA-IP groups) animals (Table IV).
Effect of preconditioning, resveratrol, and
L-NAME on NO content in urine and preconditioned
tissue. Renal tissue and urine NO, as measured by total
NO levels, was significantly lower in the ISC group as
compared with sham-operated animals. These levels were
significantly improved in the IP group as compared with
the ISC group (Fig 3). However, the nonpreconditioned
animals that received L-NAME (NA-ISC group) had total
NO levels similar to those of the ISC group. These levels
were significantly increased in the IP and NO-ISC groups.
When resveratrol was added to the group of precondi-
tioned animals receiving L-NAME (NO-NA-IP group), the
urine and tissue NO levels were similar to those found in
ion on renal function (plasma creatinine, blood urea
nimals
BUN (mg/dL) Creatinine clearance (mL/min)
14.38  2.2 0.477  0.054
75.87  7.8* 0.063  0.018*
20.01  1.08† 0.415  0.05†
15.59  1.81† 0.436  0.059†
12.25  1.09† 0.485  0.06†
69.32  5.87 0.058  0.012
17.62  2.06† 0.396  0.056†
82.25  8.9 0.050  0.01
mic group; NO-IP, resveratrol  preconditioned group; NA-IP, L-NAME
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veratrol exerted its effect through the release of NO.
DISCUSSION
Preconditioning is a simple and harmless method used
to render an organ tolerant to ischemia.30 In this study, we
examined whether the three-cycle schedule of precondi-
tioning attenuated the damage induced by sustained isch-
emia in the kidney and then determined the optimal time
window of ischemia and reperfusion. This study demon-
strates that three short periods of 2-minute ischemia pro-
tect the kidney from subsequent prolonged ischemic insult
Fig 2. Hematoxylin and eosin–stained sections of rat k
normal glomeruli and normal tubules. B, Renal cortex o
casts, andmedullary congestion. C, Kidney section of a ra
of ischemia and 5 minutes of reperfusion and 45 minute
showing only mild medullary congestion. D, Kidney secti
tubular damage. E, Kidney section of rats treated with re
almost normal morphology. F, Kidney section of rats tre
IP group showing severe tubular damage, cast formation
with resveratrol and L-NAME in the IP group showing
cast formation. H, Kidney section of rats treated with L-N
formation, and medullary congestion.by a mechanism involving NO. We have also shown thatresveratrol protects against ischemic insult through an NO-
dependent mechanism.
The destructive effects of I/R inflict direct tissue
damage and initiate a cascade of deleterious cellular
responses that lead to inflammation, cell death, and
organ failure.31,32 Renal I/R injury secondary to pro-
longed cessation of blood flow is a significant and com-
mon clinical concern.33,34 Surgical procedures involving
the aorta and renal arteries (suprarenal and juxtarenal
abdominal aortic aneurysms and renal transplantation, in
particular) result in significant postoperative renal com-
plications in the form of acute tubular necrosis and acute
s. A, Renal cortex of rats from the sham group showing
rats showing severe tubulointerstitial damage, hyaline
ted with the Prec 2/5 protocol (three cycles of 2 minutes
rolonged ischemia followed by 24 hours of reperfusion)
a rat treated with resveratrol and ISC showing only mild
rol in the ischemic preconditioning (IP) group showing
ith NG-nitro-L-arginine methyl ester (L-NAME) in the
medullary congestion. G, Kidney section of rats treated
rate tubular damage, severe medullary congestion, and









AMrenal failure.33 Therefore, ways to prevent renal dysfunc-
A-IP
ed by
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intense research interest.
The importance of reperfusion injury has several impli-
cations in clinical practice, and these results indicate that IP
may have a role in reducing renal injury during transplan-
tation or renal surgery. Many mechanisms for protection
from I/R injury induced by IP have been proposed. Un-
derlying this has been the goal of identifying a final com-
mon pathway of protection, with possible pharmacothera-
peutic implications.
This study demonstrates that acute preconditioning of
the kidney is feasible. On the basis of our preliminary
studies, it seems that three repetitive cycles of 2 minutes of
ischemia are optimal to precondition the rat kidney in vivo.
Our finding is in agreement with the findings of Cochrane
et al35; however, we did not obtain satisfactory effects with
the preconditioning protocols used by Jefayri et al36 or by
Lee and Emala.37 The beneficial effects of renal precondi-
tioning may differ from those for the heart, where the
optimal condition for IP seems to be three cycles of 5
minutes of ischemia,38 which proved ineffective in the
kidneys. According to this work, it seems that cycles involv-
ing shorter periods of preconditioning ischemia may be
Table III. Effect of resveratrol and nitric oxide synthase in
animals









, Mild; , moderate; , severe; ISC, ischemic group; IP-ISC, prec
preconditioned group; NA-IP, L-NAME  preconditioned group; NO-N
ischemic group.
Table IV. Effect of resveratrol and nitric oxide synthase in
and renal oxidative stress in preconditioned animals
Group TBARS (nmol/mg protein) GSH (m
Sham 36.8  4.12 7.89
ISC 95.2  9.23* 4.93
IP-ISC 47.58  8.66† 7.01
NO-ISC 38.25  3.38† 7.65
NO-IP 32.69  3.81† 8.59
NA-IP 92.83  8.86 4.52
NO-NA-IP 49.12  5.35† 7.19
NA-ISC 99.82  10.26 4.28
Values are expressed as mean  SEM.
GSH, Reduced glutathione; SOD, superoxide dismutase; ISC, ischemic grou
resveratrol  preconditioned group; NA-IP, L-NAME  preconditioned
L-NAME  ischemic group.
*P  .05 compared with sham.
†P  .05 compared with the ISC group (one-way analysis of variance followoptimal to protect against I/R injury in the kidney.Signaling mechanisms underlying the NO-mediated IP
process have been recently discussed. In isolated rat heart,
Lochner et al39 indicated the importance of the NO/
guanylyl cyclase/cyclic guanosine monophosphate path-
way in the cardioprotective effects of IP, by using NO
donors and inhibitors of NOS and guanylyl cyclase. It has
been demonstrated that the activation and translocation of
protein kinase C during the cardioprotective effects of IP is
NO dependent.40 The mitochondrial adenosine triphos-
phate–sensitive K channel, which contributes to the IP-
mediated myocardial protection,11 could be activated by
NO donors in ventricular myocytes.41 In addition, it has
been reported that hepatic IP is mediated by the inhibitory
action of NO on endothelin 1 overproduction induced by
I/R.7
The study by Yoshida et al42 clearly demonstrated that
resveratrol preconditions rat hearts against lethal I/R in-
jury. The anti-ischemic effect of the resveratrol was blocked
by L-NAME, an inhibitor of NO synthesis, thus indicating
that NO is the mediator of resveratrol preconditioning of
the heart. Recently, iNOS has been demonstrated in
resveratrol-induced preconditioning of the heart.25 Several
other recent articles have indicated that preconditioning
tion on morphologic changes in ischemic preconditioned









oned group; NO-ISC, resveratrol  ischemic group; NO-IP, resveratrol 
, resveratrol  L-NAME  preconditioned group; NA-ISC, L-NAME 
tion on thiobarbituric acid–reacting substances (TBARS)
104) Catalase (k/min) SOD (U/mg protein)
8 0.39  0.025 8.56  0.43
57* 0.054  0.008* 2.59  0.28*
2† 0.32  0.017† 7.12  0.62†
3† 0.38  0.02 † 7.85  0.59†
9† 0.42  0.021† 8.37  0.51†
6 0.051  0.007 2.12  0.19
9† 0.301  0.011† 6.9  0.54†
9 0.058  0.007 2.25  0.13
ISC, preconditioned group;NO-ISC, resveratrol ischemic group;NO-IP,














groupleads to protection in the kidney against I/R injury, and
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L-NAME, thus indicating the involvement of NO in the
protective effect of preconditioning in kidney.43-45 Al-
though resveratrol can scavenge peroxyl radicals in vitro, it
is generally known as a poor antioxidant.18 However, in
vivo, resveratrol functions as an antioxidant and decreases
the amount of oxidative stress developed in the ischemic
reperfused myocardium.16,25 This seemingly different be-
havior of resveratrol can be explained if indeed this com-
pound functions through the augmentation of NO. Nu-
merous articles exist in the literature demonstratingmassive
production of reactive oxygen species in the ischemic reper-
fused myocardium. NO can readily react with the superox-
ide anion to form the highly reactive peroxynitrite radical
ONOO, which in turn should preferentially react with the
thiols and ascorbates, which are also present in the heart
and kidney. In this regard, NO can function as an in vivo
antioxidant; hence, resveratrol, throughNO, can also func-
tion as a potent in vivo antioxidant.
In this study, renal I/R-induced functional and mor-
phologic damage was significantly improved by precondi-
tioning of the kidney and also by prior treatment with
resveratrol. It is interesting to note that the renal lipid
peroxidation levels were markedly reduced by the IP pro-
tocols. Furthermore, the levels of antioxidant enzymes
(GSH, catalase, and SOD) were significantly improved by
IP and resveratrol. The urinary and serumNO levels, which
were markedly decreased by I/R, were found to be signif-
Fig 3. Effect of ischemic preconditioning (IP) on tissue (A) and
urine (B) total nitric oxide (NO) levels. Values are expressed as
mean SEM. *P .05 compared with the sham group; **P .05
compared with the ISC group (one-way analysis of variance fol-
lowed by the Dunnett test). ISC, Ischemic group; IPISC, pre-
conditioned group; NO-ISC, resveratrol  ischemic group; NO-
IP, resveratrol  preconditioned group; NA-IP, L-NAME 
preconditioned group; NO-NA-IP, resveratrol  L-NAME 
preconditioned group; NA-ISC, L-NAME  ischemic group.icantly improved by IP and prior treatment with resveratrol.Pretreatment with the nonselective NOS inhibitor
L-NAME attenuated the protective effect of IP, as well as
that of resveratrol. Histopathologic studies have shown a
marked protection in the Prec 2/5 group and in the ani-
mals pretreated with resveratrol. However, prior treatment
with L-NAME abolished the protective effect of resveratrol
in ischemic (ISC) animals, and when L-NAME was given
along with resveratrol in the IP group, the morphologic
protection afforded was similar to that in IP-treated ani-
mals. This clearly indicates that resveratrol exerts its protec-
tive effect through the release of NO and also through its
antioxidant mechanism.
In conclusion, these findings suggest a marked protec-
tive effect of IP on I/R-induced acute renal failure and
demonstrate the role of NO in resveratrol-induced renal IP.
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